Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Ligand Pharmaceuticals (LGND)

Ligand completes $739 million acquisition of XOMA Royalty

Neutral Impact 4 of 5 m&a Written later

Ligand Pharmaceuticals completed its merger with XOMA Royalty on July 14, 2026, paying $39.00 per share in cash plus one contingent value right (CVR) per share, for a total equity value of approximately $739 million. In connection with the closing, Ligand entered an amended credit agreement providing a $125.0 million revolving credit facility maturing September 12, 2028. Ligand expects the deal to be immediately accretive, but CVR holders may receive no payment, depending on the outcome of pending litigation at XOMA Royalty.

Key points

  • Consideration: $39.00 per XOMA Royalty share in cash plus one CVR per share, with total equity value of approximately $739 million
  • Ligand expects the deal to add approximately $0.50 per share to projected 2026 adjusted EPS and $1.50 per share to projected 2027 adjusted EPS
  • Amended Credit Agreement provides a $125.0 million revolving credit facility maturing September 12, 2028, secured by certain collateral and guaranteed by material domestic subsidiaries
  • Ligand will provide an updated 5-year outlook at its Investor Day on December 8, 2026

The filing

CompanyLigand Pharmaceuticals (LGND)
Form8-K, current report
Filed with the SECJul 14, 2026, 9:20 AM ET
Accession number0001193125-26-302660

Items reported: 1.01 Material Definitive Agreement2.01 Acquisition or Disposition Completed2.03 New Direct Financial Obligation7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.